Evonik Industries AG · XETR:EVK

Evonik Industries — Investor Presentation (June 2017)

97 slides from Evonik Industries's investor presentation, June 2017

  1. Slide 1: Evonik – Power to create. Company presentation June 2017

    Slide 1: Evonik – Power to create. Company presentation June 2017

    Evonik Power to create. Company presentation June 2017 1

  2. Slide 2: Table of contents

    Slide 2: Table of contents

    Table of contents 1. Evonik at a glance 2. Strategy Update 3. Financials Q1 2017 4. Appendix 2

  3. Slide 3: A strong basis in Specialty Chemicals

    Slide 3: A strong basis in Specialty Chemicals

    A strong basis in Specialty Chemicals Market Customer Technology Unique brand Qualified leadership proximity leadership recognition employees Leading market Leading and Highly qualified Almost 90% positions in proprietary technology of direct sales platforms in workforce 80% via as key factor for a

  4. Slide 4: Three segments with differentiated management

    Slide 4: Three segments with differentiated management

    Three segments with differentiated management Group financials 2016 Sales Adj. EBITDA Margin ROCE €12,732 m €2,165 m 17.0% 14.0% Growth Efficiency Nutrition Resource Performance & Care Efficiency Materials Sales Adj. EBITDA / Margin Sales Adj. EBITDA / Margin Sales Adj. EBITDA / Margin €4,316 m €1,0

  5. Slide 5: Balanced regional and end market split

    Slide 5: Balanced regional and end market split

    Balanced regional and end market split Sales by region End market split Agriculture Renewable energies Paper & printing Other Electrical & electronics Food & animal feed Germany Metal & oil products Asia-Pacific Paints & coatings1 Pharmaceuticals Consumer & Other industries personal care Central & S

  6. Slide 6: Evonik management team with clear responsibilities

    Slide 6: Evonik management team with clear responsibilities

    Evonik management team with clear responsibilities Executive Board Group Strategy Chemistry & Innovation Financials HR Christian Dr. Harald Ute Thomas Kullmann Schwager1 Wolf Wessel Chairman of the Deputy Chairman Chief Financial Chief Human Executive Board of the Executive Officer Resources Officer

  7. Slide 7: RAG-Stiftung as long-term shareholder with focus on attractive returns

    Slide 7: RAG-Stiftung as long-term shareholder with focus on attractive returns

    “RAG-Stiftung” as long-term shareholder with focus on attractive returns Ownership structure RAG-Stiftung  A foundation with the obligation to finance the perpetual liabilities arising from the cessation of hard-coal mining in Germany  From 2019 onwards, annual cash out of ~ €220 m expected Free f

  8. Slide 8: Reliable and attractive dividend policy

    Slide 8: Reliable and attractive dividend policy

    Reliable and attractive dividend policy Payout ratio 48% 58%  Sustainable dividend growth over the last years: 8% CAGR between 2008 and 2016  Dividend for 2016 on attractive 2015 level Dividend (in €) despite lower adjusted net income 1.15 1.15 +8% CAGR  Attractive dividend yield ~ 4%  Reliable

  9. Slide 9: Table of contents

    Slide 9: Table of contents

    Table of contents 1. Evonik at a glance 2. Strategy Update 3. Financials Q1 2017 4. Appendix 9

  10. Slide 10: Significant progress achieved over last 3 years

    Slide 10: Significant progress achieved over last 3 years

    Significant progress achieved over last 3 years Growth Efficiency 2017 onwards Further balancing of Differentiated Evonik’s portfolio and management of segments financial profile 2014 2015 2016 2017 … New Corporate Acquisitions structure 10

  11. Slide 11: Building a best-in-class specialty chemicals company

    Slide 11: Building a best-in-class specialty chemicals company

    Building a best-in-class specialty chemicals company 11

  12. Slide 12: Targeting excellence in three strategic focus areas

    Slide 12: Targeting excellence in three strategic focus areas

    Targeting excellence in three strategic focus areas Portfolio: More balanced & more specialty Profitable Customer- Growth Open & focused performance-oriented innovation culture 12

  13. Slide 13: Portfolio strategy: More balanced – more specialty

    Slide 13: Portfolio strategy: More balanced – more specialty

    Portfolio strategy: „More balanced – more specialty“ Focus on businesses with specialty chemicals characteristics Low cyclicality; Customer-specific products low raw material dependency and services Above- average growth and margins Mission-critical solutions High customer proximity enabling value-b

  14. Slide 14: Building on our strengths: developing growth segments and businesses

    Slide 14: Building on our strengths: developing growth segments and businesses

    Building on our strengths Developing our growth segments and businesses NUTRITION & CARE RESOURCE EFFICIENCY PERFORMANCE MATERIALS €4.3 bn €4.5 bn €3.2 bn Mature Mature Mature businesses businesses businesses Growth Growth businesses businesses Meeting specialty chemicals characteristics Focus of ca

  15. Slide 15: Strategic growth focus: four growth engines

    Slide 15: Strategic growth focus: four growth engines

    Strategic growth focus Four growth engines as drivers for profitable & balanced growth NUTRITION & CARE RESOURCE EFFICIENCY Health & Care Smart Materials Four growth Specialty Additives engines Animal Nutrition 15

  16. Slide 16: Four growth engines: growth drivers and product examples

    Slide 16: Four growth engines: growth drivers and product examples

    Four growth engines Growth drivers and product examples Growth trends and drivers Product examples Market growth  More sophisticated requirements on additive effects Coating Additives Specialty Additives  Need for increased product performance and PU-Additives 5-6% “Small volume, big impact” effic

  17. Slide 17: Thorough review process of key drivers for value creation

    Slide 17: Thorough review process of key drivers for value creation

    Thorough review process of key drivers for value creation Capital Cost allocation Continuous & competitiveness  Targeted investments for disciplined  Factor cost (over-) compensation as sustainable growth efficiency target for all businesses process  Value-adding acquisitions  Focus on value-cre

  18. Slide 18: Targeted and disciplined M&A approach

    Slide 18: Targeted and disciplined M&A approach

    Targeted and disciplined M&A approach Air Products Huber Silica Dr. Straetmans Performance Materials Purchase price ~ €3.5 bn ~ €600 m ~ €100 m EBITDA margin >20% >20% ~20% Market growth ~4-5% ~4-6% ~10% Business Highly attractive strategic fit, seamless integration into existing businesses Discipli

  19. Slide 19: Leading Innovation

    Slide 19: Leading Innovation

    Leading Innovation Ambitious targets, clear strategy and inspiring culture Innovation Innovation Innovation Targets Strategy Culture  Increase of innovation pipeline value  Balanced innovation portfolio management  Guiding principles of innovation  16% contribution of innovation  Fostering disr

  20. Slide 20: Innovation: Our goals

    Slide 20: Innovation: Our goals

    Innovation: Our goals R&D rate Evonik growth fields 3 % on Group level; €1 billion additional turnover 4-6 % in growth engines by 2025 Our Goals Products/applications younger than five years 16 percent share of overall sales (medium term) 20

  21. Slide 21: Corporate culture drives performance

    Slide 21: Corporate culture drives performance

    Corporate culture drives performance Business focus Best-in-class team  We take action and initiate change  We build on openness, trust and respect  We reward measured risk taking  We assign responsibility and demand  We promise and deliver – with conviction, accountability clarity and consiste

  22. Slide 22: Strategic agenda reflected in ambitious financial targets

    Slide 22: Strategic agenda reflected in ambitious financial targets

    Strategic agenda reflected in ambitious financial targets Structurally lifting EBITDA margin and driving balanced growth Historic margin range (in %) Targets going forward (over the cycle) Structurally lift EBITDA margin 19.0 into sustainably higher range of 18-20% 18.3 18.5 18.2 Above-average volum

  23. Slide 23: Summary: Building a best-in-class specialty chemicals company

    Slide 23: Summary: Building a best-in-class specialty chemicals company

    Summary Building a best-in-class specialty chemicals company Executing our … for structural uplift strategic agenda… in profitability & growth Portfolio 18-20% EBITDA margin Growth GDP+ volume growth Innovation Culture 23

  24. Slide 24: Table of contents

    Slide 24: Table of contents

    Table of contents 1. Evonik at a glance 2. Strategy Update 3. Financials Q1 2017 4. Appendix 24

  25. Slide 25: Highlights Q1 2017

    Slide 25: Highlights Q1 2017

    Highlights Q1 2017 Good start into the year Volume growth Adj. EBITDA Free cash flow Outlook confirmed +8 % €612 m €57 m (vs. €2.2-2.4 bn (yoy) (vs. €653 m) €208 m in H1) (vs. €208 m in H1) Strong volume growth Strong earnings growth in Positive free cash flow, Fully on track to reach across all thr

  26. Slide 26: Consistent strategy execution

    Slide 26: Consistent strategy execution

    Consistent strategy execution Breakthrough innovation and targeted M&A  JV for omega-3 fatty acids from natural marine algae Breakthrough  Breakthrough to reduce impact on ocean resources innovation  JV to invest US$ 200 m into commercial-scale production facility in the United States  Acquisiti

  27. Slide 27: Swift and smooth integration of Air Products specialty additives

    Slide 27: Swift and smooth integration of Air Products specialty additives

    Swift and smooth integration process of Air Products specialty additives Integration activities focus on joint operating model and systematic transition Business continuity Integration Business / Processes / People / Systems Q1 2017 Q2 2017 Q3 2017 Q4 2017 2018 ff Transition and synergies Day 1 Lead

  28. Slide 28: Financial highlights Q1 2017

    Slide 28: Financial highlights Q1 2017

    Financial highlights Q1 2017 Strong volume growth and sequentially further improving price trend Sales +19% Q1 16 vs. Q1 17 Adj. EBITDA (in € m) +8% (in € m) 3,683 / margin (in %) 565 612 3,106 Volume Price +8%   -1%  FX Other1 in % 18.2 16.6 Q1 16 Q1 17 +2%  +10%   Q1 16 Q1 17 +2% -€3,399 m A

  29. Slide 29: Free Cash Flow Q1 2017

    Slide 29: Free Cash Flow Q1 2017

    Free Cash Flow Q1 2017 Positive free cash flow below strong prior-year level Operating Cash Flow Investing Cash Flow Free Cash Flow (cont. op. in € m) (cont. op. in € m)1 (cont. op. in € m)2 (before dividends and divestments) 152 338 277 57 Q1 2016 Q1 2017 Q1 2016 Q1 2017  Positive FCF -186 -220 

  30. Slide 30: Resource Efficiency: Evonik's major earnings contributor

    Slide 30: Resource Efficiency: Evonik's major earnings contributor

    Resource Efficiency Evonik’s major earnings contributor More than half of Group earnings in RE … … as high-value specialty chemicals business Q1 2017 adj. EBITDA share Resilient:  Diversified end markets and businesses Strong growth:  Consistent volume and earnings growth Attractive margin:  Well

  31. Slide 31: Resource Efficiency: strong volume growth and high margins

    Slide 31: Resource Efficiency: strong volume growth and high margins

    Resource Efficiency Strong volume growth and consistently high margins Sales (in € m) Adj. EBITDA (in € m) / margin (in %) +24% +21% 1,391 310 1,120 1,156 1,117 256 270 262 1,081 189 22.9 23.4 23.5 17.5 22.3 Q1 16 Q2 16 Q3 16 Q4 16 Q1 17 Q1 16 Q2 16 Q3 16 Q4 16 Q1 17  Strong volumes across virtuall

  32. Slide 32: Nutrition & Care: strong volume growth, lower price level

    Slide 32: Nutrition & Care: strong volume growth, lower price level

    Nutrition & Care Strong volume growth, earnings impacted by lower price level Sales (in € m) Adj. EBITDA (in € m) / margin (in %) +7% -35% 1,047 1,111 1,066 1,093 1,124 293 264 239 209 189 28.0 23.8 22.4 19.1 16.8 Q1 16 Q2 16 Q3 16 Q4 16 Q1 17 Q1 16 Q2 16 Q3 16 Q4 16 Q1 17  Health Care starting str

  33. Slide 33: Performance Materials: strong start into 2017

    Slide 33: Performance Materials: strong start into 2017

    Performance Materials Strong start into 2017 driven by MMA and C4 businesses Sales (in € m) Adj. EBITDA (in € m) / margin (in %) +26% +148% 972 159 772 829 797 846 105 104 98 64 8.3 12.7 13.0 11.6 16.4 Q1 16 Q2 16 Q3 16 Q4 16 Q1 17 Q1 16 Q2 16 Q3 16 Q4 16 Q1 17  MMA/PMMA business with excellent per

  34. Slide 34: Targeting earnings growth for FY 2017

    Slide 34: Targeting earnings growth for FY 2017

    Targeting earnings growth for FY 2017 Outlook for 2017 confirmed Outlook 2017 Adj. EBITDA €2.4 bn Higher sales (2016: €12.7 bn) Outlook range Adj. EBITDA between €2.2 bn and €2.4 bn €2.2 bn (2016: €2.165 bn) 2017E 34

  35. Slide 35: Segment outlook FY 2017

    Slide 35: Segment outlook FY 2017

    Segment outlook FY 2017 (Huber Silica business not included in outlook) Nutrition & Care Resource Efficiency Performance Materials EBITDA lower than in previous year Considerably higher EBITDA Considerably higher EBITDA  Positive earnings contribution from  Positive earnings contribution from  Im

  36. Slide 36: Additional indications for 2017 – excluding Huber Silica

    Slide 36: Additional indications for 2017 – excluding Huber Silica

    Additional indications for 2017 – excluding Huber Silica  Air Products specialty Adj. EBITDA of around €250 m including first synergies of €10-20 m; Sales and adj. EBITDA will be allocated additives business roughly equally between N&C and RE  ROCE Above cost of capital (10.0% before taxes), but p

  37. Slide 37: © evonik

    Slide 37: © evonik

    © evonik

  38. Slide 38: Appendix

    Slide 38: Appendix

    Appendix 1. Acquisition of Air Products specialty additives business 2. Acquisition of Huber Silica 3. Segment overview 4. Financials 5. Upcoming events 38

  39. Slide 39: Acquisition of Air Products Performance Materials activities

    Slide 39: Acquisition of Air Products Performance Materials activities

    Acquisition of Air Products (APD) Performance Materials activities Creating a global leader in Specialty & Coating Additives Impacted Evonik businesses Creating a global leader APD Performance Materials in Specialty & Coating Additives Comfort & Insulation Polyurethane Personal Care Additives Househ

  40. Slide 40: Complementary fit of Evonik and Air Products specialty additives

    Slide 40: Complementary fit of Evonik and Air Products specialty additives

    Excellent complementary fit of Evonik and Air Products specialty additives businesses Evonik Target industries APD Performance Materials High value additives  PU foam stabilizers  PU foam catalysts for PU foam  Amine-based crosslinkers  Isophorone-based crosslinkers Additives/Ingredients  Epoxy

  41. Slide 41: Strategic and operational fit leading to significant synergies

    Slide 41: Strategic and operational fit leading to significant synergies

    Excellent strategic and operational fit leading to significant synergies  Excellent strategic fit  Complementary product portfolio  Strong supply chains and manufacturing base Cost synergies Revenue synergies Broader Leveraging product and Synergies Overhead Production Procurement each other’s ap

  42. Slide 42: Synergy ramp-up on track for combined businesses

    Slide 42: Synergy ramp-up on track for combined businesses

    Synergy ramp-up on track for combined businesses Implementation schedule of Air Products specialty additives acquisition (in € m) Annual synergies One-time costs 80 Total 70 ~ €70 m p.a. 60 Annual synergies (USD80 m) ~50 50 40 30 20 One-time integration ~10 ~10 ~ €75 m 10 costs1 ~5 - 0 2016 2017 201

  43. Slide 43: Synergy potential and tax benefits leading to an attractive price

    Slide 43: Synergy potential and tax benefits leading to an attractive price

    Synergy potential and tax benefits leading to an attractive price Enterprise Value (in $ m) Adjusted EBITDA2 (in $ m) EV / EBITDA 2016E ~3,800 9.9x ~330 incl. synergies and tax benefits ~520 ~80 EV / EBITDA 2016E ~3,280 15.2x 250 excl. synergies and tax benefits EPS accretive Incl. tax benefits NPV

  44. Slide 44: Appendix

    Slide 44: Appendix

    Appendix 1. Acquisition of Air Products specialty additives business 2. Acquisition of Huber Silica 3. Segment overview 4. Financials 5. Upcoming events 44

  45. Slide 45: Huber Silica: a profitable and resilient player in Silica

    Slide 45: Huber Silica: a profitable and resilient player in Silica

    Huber Silica A profitable and resilient player in Silica J.M. Huber Corporation  Huber Silica is part of US-based company J.M. Huber Corporation  Family-owned, founded in 1883  Headquarter in Edison, New Jersey Huber Silica business EBITDA 2016E: Sales 2016E:  Technology- and solution-driven bus

  46. Slide 46: Acquisition of Huber Silica

    Slide 46: Acquisition of Huber Silica

    Acquisition of Huber Silica Access to new highly attractive silica applications for Evonik Evonik‘s focus areas in Silica Huber’s focus areas in Silica Complementary Tire applications Dental Coatings  Attractive growth rates: Life Science Specialties Industrial 4-6% Specialties Combined sales1: > €

  47. Slide 47: Key applications

    Slide 47: Key applications

    Excellent fit due to complementary applications and portfolio strengths Evonik Precipitated silica Huber Silica  Established industries Dental with high quality standards and global key accounts  “Green tires” with stronger Key applications Tire growth, Dental with higher resilience  Combining Ev

  48. Slide 48: Diversified exposure with attractive growth rates

    Slide 48: Diversified exposure with attractive growth rates

    Diversified exposure with attractive growth rates Resource Efficiency and Convenience as major growth drivers  Abrasive silica for cleaning and whitening Dental 4% p.a.  Thickening agent for toothpaste  Reduced rolling resistance of “Green Tires” Tire 5-7% p.a.  Increased tensile strength and ha

  49. Slide 49: Optimizing the regional production setup

    Slide 49: Optimizing the regional production setup

    Optimizing the regional production setup Dedicated plants for specific silica types in each major region Asset optimization: Situation today: North America Europe  Plants producing different silica types for several applications Asia New setup after integration:  Asset optimization towards one ded

  50. Slide 50: Partial backward integration in precipitated silica

    Slide 50: Partial backward integration in precipitated silica

    Evonik will improve its position in precipitated silica through partial backward integration Partial backward integration into sodium silicate (water glass)  Currently Evonik buys required Silicon dioxide Customer Sodium Silicate Precipitated silica sodium silicate externally (Sand) industries  Ac

  51. Slide 51: Significant synergies from strategic and operational fit

    Slide 51: Significant synergies from strategic and operational fit

    Significant synergies driven by excellent strategic and operational fit  Excellent strategic fit  Complementary product portfolio  manufacturing base Strong supply chains and S Production, Logistic ~10 Y N  Total synergies: ~ $20 m E R Procurement, Raw materials ~5 G  All measures expected I to

  52. Slide 52: Synergies and strategic buyer position leading to attractive valuation

    Slide 52: Synergies and strategic buyer position leading to attractive valuation

    Synergies and position as strategic buyer leading to attractive valuation Enterprise Value (in $ m) EV / EBITDA 2016E EBITDA incl. synergies (in $ m) ~7 x 630 incl. synergies & tax benefits 80 80 20 EV / EBITDA 2016E 60 550 10.5 x excl. synergies & tax benefits EV excl. NPV of EV incl. EBITDA Sustai

  53. Slide 53: Target market example: dental silica

    Slide 53: Target market example: dental silica

    Target market example: dental silica: Silica as key component for improved oral hygiene and teeth retention Dental usage of silica Silica as… … key component with uniquely modified particles to achieve:  Abrasive dirt and plaque abrasion without enamel damage  Thickener rheology modification for p

  54. Slide 54: Appendix

    Slide 54: Appendix

    Appendix 1. Acquisition of Air Products specialty additives business 2. Acquisition of Huber Silica 3. Segment overview 4. Financials 5. Upcoming events 54

  55. Slide 55: Evonik Group: 22 Business Lines grouped in 3 segments

    Slide 55: Evonik Group: 22 Business Lines grouped in 3 segments

    Evonik Group 22 Business Lines grouped in 3 segments Resource Performance Nutrition & Care Efficiency Materials Sales Adj. EBITDA / Margin Sales Adj. EBITDA / Margin Sales Adj. EBITDA / Margin €4,316 m €1,006 m / 23.3% €4,473 m €977 m / 21.8% €3,145 m €371 m / 11.4% Animal Nutrition Silica Performan

  56. Slide 56: Nutrition & Care: fulfilling human needs

    Slide 56: Nutrition & Care: fulfilling human needs

    Nutrition & Care Fulfilling human needs in a globalizing world Key characteristics Adj. EBITDA (€ m) and margin (%) End market split  High degree of customer intimacy and market know-how 27.0 25.8 25.0 22.1 20.8 29.1 23.3  Enabling our customers to deliver differentiating solutions in their market

  57. Slide 57: Nutrition & Care Business Line overview (1/2)

    Slide 57: Nutrition & Care Business Line overview (1/2)

    Nutrition & Care Business Line overview (1/2) Animal Nutrition Baby Care Personal Care Household Care  Methionine  Superabsorbents  Actives  Fabric conditioners Key  Lysine, Threonine,  Emulsifiers  Specialty surfactants products Tryptophan  Conditioners  Feed additives and services  Baby

  58. Slide 58: Nutrition & Care Business Line overview (2/2)

    Slide 58: Nutrition & Care Business Line overview (2/2)

    Nutrition & Care Business Line overview (2/2) Health Care Comfort & Insulation Interface & Performance  Pharmaceutical coatings  Foam stabilizers  Release coatings Key  Active pharma ingredients  Catalysts  Super spreading additives products  Pharma grade amino acids  Release agents  Drug d

  59. Slide 59: Putting Methionine into perspective

    Slide 59: Putting Methionine into perspective

    Business Line Animal Nutrition Putting Methionine into perspective Important product for Evonik, but not the core of our investment case Leading position in Methionine with … … lowered dependency  Global market and technology leader  Well-invested global asset setup Rest of Methionine: Evonik Evon

  60. Slide 60: Natural marine algal oil as sustainable omega-3 alternative

    Slide 60: Natural marine algal oil as sustainable omega-3 alternative

    Business Line Animal Nutrition Natural marine algal oil is a sustainable alternative solution for omega-3 fatty acids used in aquacultures 2.6 kg “fish-in-fish-out” ratio 1 kg Conventional aquaculture Natural marine Salmon Zooplankton Fish Fishing vessel Fish oil algae aquaculture DSM and Evonik inn

  61. Slide 61: Algal oil advantages versus other omega-3 sources

    Slide 61: Algal oil advantages versus other omega-3 sources

    Business Line Animal Nutrition Algal oil as a high-quality source of omega-3 for the use in animal nutrition has many advantages Advantages versus other omega-3 sources EPA+DHA 1 kg of our EPA and DHA algal oil Source can replace 60 kg wild catch fish 3 Liquid product Natural algae (not genetically

  62. Slide 62: DSM and Evonik joint venture for omega-3 from algae

    Slide 62: DSM and Evonik joint venture for omega-3 from algae

    Business Line Animal Nutrition DSM and Evonik establish joint venture for omega-3 fatty acids from natural marine algae for animal nutrition  DSM and Evonik to found a 50:50 joint venture to be named VeramarisTM, headquartered in The Netherlands  Joint venture for high value omega-3 fatty acid pro

  63. Slide 63: Key components for sustainable aquacultures

    Slide 63: Key components for sustainable aquacultures

    Business Line Animal Nutrition Evonik offers key components for the development of sustainable aquacultures Start of evolution towards sustainable salmon diet Target: “vegetarian” diet without fish meal and -oil Traditional diet More sustainable diet Further reduction of fish input enabled by amino

  64. Slide 64: Acquisition of Dr. Straetmans

    Slide 64: Acquisition of Dr. Straetmans

    Business Line Personal Care Acquisition of Dr. Straetmans Sustainable preservation with state of the art multifunctionals Preservatives Market shift to high-growth non-traditional preservatives  Preservatives are an essential part of any cosmetics ~€500M CAGR ’16-’21 formulation preventing product

  65. Slide 65: Dr. Straetmans helping Personal Care become wide technology player

    Slide 65: Dr. Straetmans helping Personal Care become wide technology player

    Business Line Personal Care Acquisition of Dr. Straetmans Helping Evonik Personal Care to become a wide technology player Evonik Personal Care Base Products Specialties Fragrances (Secondary Functional Active Surfactants) 1 2 Ingredients Ingredients 1 Chassis  Perf. Additives 2 Tip-in Ingredients T

  66. Slide 66: Harvesting substantial value from Technology M&A

    Slide 66: Harvesting substantial value from Technology M&A

    Business Line Health Care Harvesting substantial value from Technology M&A Building up competences and additional solution portfolio by Technology M&A Evonik Healthcare as enabler and strategic partner for Transferra Nanoscioence Inc. (2016) LIPEX® pharma industry Lipid Nanoparticle • Unique technol

  67. Slide 67: Resource Efficiency: innovative products for resource-efficient solutions

    Slide 67: Resource Efficiency: innovative products for resource-efficient solutions

    Resource Efficiency Innovative products for resource-efficient solutions Key characteristics Adj. EBITDA (€ m) and margin (%) End market split  Focus on performance-impacting and value-driving components 18.4 19.9 21.4 21.3 20.7 20.9 21.8  Minor share of cost in most end products 977 Automotive, 

  68. Slide 68: Resource Efficiency Business Line overview (1/3)

    Slide 68: Resource Efficiency Business Line overview (1/3)

    Resource Efficiency Business Line overview (1/3) Silica Oil Additives Crosslinkers  Precipitated silica  Lubricant additives (viscosity modifiers)  Crosslinkers for composites, elastomers Key  Fumed silica and coatings products  Special oxides  Silicone rubber  Automotive lubes  Composites M

  69. Slide 69: Resource Efficiency Business Line overview (2/3)

    Slide 69: Resource Efficiency Business Line overview (2/3)

    Resource Efficiency Business Line overview (2/3) Active Oxygens High Performance Polymers Coating & Adhesive Resins  Hydrogen peroxide  High perf. polyamide (PA12)  Functional resins Key  Polyetheretherketone (PEEK)  Adhesive hot melts products  Membranes and Polyimide fibres  Heat sealants 

  70. Slide 70: Resource Efficiency Business Line overview (3/3)

    Slide 70: Resource Efficiency Business Line overview (3/3)

    Resource Efficiency Business Line overview (3/3) Silanes Coating Additives Catalysts  Chlorosilanes  Additives for eco-friendly and high solid  Activated base metal catalysts Key  Organofunctional silanes industrial coatings  Precious metal catalysts products  Rubber silanes  Catalysts for in

  71. Slide 71: Performance Materials: integrated production platforms

    Slide 71: Performance Materials: integrated production platforms

    Performance Materials Integrated production platforms for efficient production of rubber and plastic intermediates Key characteristics Adj. EBITDA (€ m) and margin (%) End market split  Strong integrated production platforms  Leading cost positions 15.8 18.8 16.9 10.6 8.5 9.0 11.4  Favorable raw

  72. Slide 72: Performance Materials Business Line overview (1/2)

    Slide 72: Performance Materials Business Line overview (1/2)

    Performance Materials Business Line overview (1/2) Performance Intermediates Methacrylates Acrylic Products  Butadiene  Plasticizers (INA &  Methylmethacrylate (MMA) &  Acrylic sheets and semi-finished Key  MTBE DINP) application monomers products (Plexiglas®/ Acrylite®) products  Butene-1  M

  73. Slide 73: Performance Materials Business Line overview (2/2)

    Slide 73: Performance Materials Business Line overview (2/2)

    Performance Materials Business Line overview (2/2) Agrochemicals & Polymer Additives Functional Solutions CyPlus Technologies  Triacetonamine  Alkoxides  Sodium cyanide Key  Crosslinkers (e.g. sodium methylate)  Potassium cyanide products  Precursors for crop protection  Polymer additives  A

  74. Slide 74: Performance Intermediates (C4 chain)

    Slide 74: Performance Intermediates (C4 chain)

    Performance Intermediates (C4 chain) Fully integrated production platform in Europe Capacity overview Key success factors  Leading, cost efficient technology End markets Rubber platform with more than 30 years Fuel additive of experience Evonik Butadiene Polyethylene product 320 kt MTBE 675 kt co-m

  75. Slide 75: Appendix

    Slide 75: Appendix

    Appendix 1. Acquisition of Air Products specialty additives business 2. Acquisition of Huber Silica 3. Segment overview 4. Financials 5. Upcoming events 75

  76. Slide 76: Segment performance FY 2016

    Slide 76: Segment performance FY 2016

    Resource Efficiency and Performance Materials with strong earnings growth Segment performance FY 2016 Nutrition & Care Resource Efficiency Performance Materials Adj. -30% +9% +20% EBITDA (in € m) 1,435 896 977 371 309 1,006 Margin (in %) 29.1 23.3 20.9 21.8 9.0 11.4 2015 2016 2015 2016 2015 2016 Sal

  77. Slide 77: Capex with significant decrease since 2013

    Slide 77: Capex with significant decrease since 2013

    Investments Capex with significant decrease since 2013 – focus on growth segments Capex spending (in € m)  Capex has considerably declined since 2013  Clear focus on the two growth segments  Sustainable capex level going forward: ~€900 m  Sizable investment projects will result in slightly eleva

  78. Slide 78: Investments: selective, smaller projects announced for 2017/18

    Slide 78: Investments: selective, smaller projects announced for 2017/18

    Investments Selective, smaller projects announced for 2017/18 Major projects successfully completed … … and selective, smaller projects with start-up planned for 2017/18 C4 expansion Polyimide membrane exp. Germany, Belgium Austria Rationale: feedstock diversification Start-up: 2017 Volume: <50 m Oi

  79. Slide 79: Cost improvement integral part of Evonik's DNA

    Slide 79: Cost improvement integral part of Evonik's DNA

    Efficiency Cost improvement integral part of Evonik’s DNA 2009 2010 2011 2012 2013 2014 2015 2016 Measures with savings €500 m  €500 Operational potential >€500 m Excellence already in m by end of 2016 On Track On Track 2.0 implementation Measures with savings Administration potential >€100 m Excel

  80. Slide 80: Financial policy: maintaining solid investment grade rating

    Slide 80: Financial policy: maintaining solid investment grade rating

    Financial policy Maintaining a solid investment grade rating A- A3 stable BBB+ (stable) Baa1 /stable BBB+ BBB+ /stable Rating affirmed at BBB+ stable on May 6, 2016 shortly after Air Baa1 stable Products specialty additives business acquisition announcement Investment BBB grade  Will enhance Evonik

  81. Slide 81: Debt structure: balanced maturity profile

    Slide 81: Debt structure: balanced maturity profile

    Debt structure Balanced maturity profile (in € m as of 31 March 2017)  Three-tranche bonds with a total value of €1.9 billion successfully issued in 1,600 September 2016, maturing in 2021, 1,400 2024 and 2028 1,200  Proceeds were used for financing of Air 1,000 Products specialty additives busines

  82. Slide 82: Pensions: funding overview

    Slide 82: Pensions: funding overview

    Pensions Pension funding overview as of Dec 31, 2016  Pensions very long-term, patient debt (>16 years) with no funding Unfunded Pension fund / obligations in Germany (~ pension reinsured support 28% provision on 33% fund  DBO level in 2016 of €11.6 bn; balance sheet) Increase of €1.1 bn vs. 2015

  83. Slide 83: Pensions: breakdown of P&L and cash flow effects

    Slide 83: Pensions: breakdown of P&L and cash flow effects

    Pensions Breakdown of P&L and cash flow effects in € m P&L item / KPI 2015 2016 Annual report ‘16 Current service costs Adj. EBITDA -191 -180 p. 161 Interest costs Net interest expense -281 -297 p. 161 P&L Exp. return on plan assets Net interest expense +185 +207 p. 162 / 163 Other Adj. EBITDA -40 -

  84. Slide 84: Pensions: sensitivity to discount rate changes

    Slide 84: Pensions: sensitivity to discount rate changes

    Pensions Sensitivity to discount rate changes Sensitivity analysis1: Increase (decrease) in discount rate by 100 bp in year x Impact in year x Impact in year x+1  Personnel costs: no impact  Personnel costs: decrease (increase) due to lower (higher) service costs  Finance costs: no impact  Finan

  85. Slide 85: Net debt development

    Slide 85: Net debt development

    Net debt development (in € m) Net financial debt Pension provisions Total leverage1 Net  Majority of debt consists of long-dated pension 2,760 3,553 2,251 2,741 6,111 obligations; average life of DBO exceeds 15 debt years  Pension provisions are partly balanced by 3,823 corresponding deferred tax

  86. Slide 86: Financial track record

    Slide 86: Financial track record

    Financial track record Sales (in € m) Adj. EBITDA (in € m) / margin1 Carbon Black/Real Estate 16.1% 18.3% 19.0% 18.5% 15.7% 14.6% 18.2% 17.0% 13,300 14,540 13,365 12,708 12,917 13,507 12,732 2,365 2,768 2,467 2,465 10,518 1,989 1,882 2,165 1,607 11,701 13,316 2,439 9,267 2,022 1,374 2009 2010 2011 2

  87. Slide 87: Segment overview by quarter

    Slide 87: Segment overview by quarter

    Segment overview by quarter Sales (in € m) FY 2015 Q1/16 Q2/16 Q3/16 Q4/16 FY 2016 Q1/17 Nutrition & Care 4,924 1,047 1,111 1,066 1,093 4,316 1,124 Resource Efficiency 4,279 1,120 1,156 1,117 1,081 4,473 1,391 Perf. Materials 3.435 772 829 797 846 3,245 972 Services 828 166 163 173 180 683 193 Corpo

  88. Slide 88: Balanced regional and end market split

    Slide 88: Balanced regional and end market split

    Balanced regional and end market split Sales by region End market split Agriculture Renewable energies Paper & printing Other Electrical & electronics Food & animal feed Germany Metal & oil products Asia-Pacific Paints & coatings1 Pharmaceuticals Consumer & Other industries personal care Central & S

  89. Slide 89: Raw material split

    Slide 89: Raw material split

    Raw material split Total procurement volume 2016 (in € m) Oil price link of raw material spend1 (examples) Bio Logistic & Packaging  Dextroxe Energy  Fatty alcohols (incl. natural gas)  Tallow fatty acid Fossil  Fatty acids  Crack C4  tallow  Propylene ~€7.6 bn ~€4.5 bn  Acrylic acid Raw mat

  90. Slide 90: Management compensation

    Slide 90: Management compensation

    Management compensation Fixed salary  To be paid in cash for each financial year on a monthly basis ~1/3  To be paid out in cash annually  Factor of between 0.8 and 1.2 to take into account the achievement of further individual targets Bonus  Pay-out calculated on the basis of the achievement of

  91. Slide 91: Innovation excellence: Evonik growth fields

    Slide 91: Innovation excellence: Evonik growth fields

    Innovation excellence: Evonik growth fields Leveraging our core competencies into highly attractive markets Megatrends Health & Nutrition Resource Efficiency Globalization Evonik Growth Fields Sustainable Nutrition Advanced Food Ingredients Healthcare Solutions Additional contribution Cosmetic Solut

  92. Slide 92: Evonik's sustainability performance publicly recognized

    Slide 92: Evonik's sustainability performance publicly recognized

    Evonik’s sustainability performance publicly recognized Our sustainability approach 2016: Included in DJSI World and Europe  Evonik well positioned in various ratings & rankings, e.g.  Sustainability is a core element in our corporate claim  Investor CDP (A-; MDAX index/country leader) “Power to

  93. Slide 93: Appendix

    Slide 93: Appendix

    Appendix 1. Acquisition of Air Products specialty additives business 2. Acquisition of Huber Silica 3. Segment overview 4. Financials 5. Upcoming events 93

  94. Slide 94: Upcoming IR events

    Slide 94: Upcoming IR events

    Upcoming IR events Conferences & Roadshows Upcoming Events & Reporting Dates Credit Suisse Global Chem. & Ag. Conference, 20 June 3 August 2017 Q2 2017 reporting London 23 June Deutsche Bank dbAccess Conference, Berlin 3 November 2017 Q3 2017 reporting 30-31 August Roadshow USA 6 March 2018 FY 2017

  95. Slide 95: Evonik Investor Relations team

    Slide 95: Evonik Investor Relations team

    Evonik Investor Relations team Tim Lange Janine Kanotowsky Head of Investor Relations Team Assistant +49 201 177 3150 +49 201 177 3146 tim.lange@evonik.com janine.kanotowsky@evonik.com Daniel Györy Kai Kirchhoff Investor Relations Manager Investor Relations Manager +49 201 177 3147 +49 201 177 3145

  96. Slide 96: Disclaimer

    Slide 96: Disclaimer

    Disclaimer In so far as forecasts or expectations are expressed in this presentation or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the oper

  97. Slide 97: © evonik

    Slide 97: © evonik

    © evonik

Source: Internet Archive copy of corporate.evonik.de

More decks from Evonik Industries AG

All 19 Evonik Industries decks